tradingkey.logo
tradingkey.logo
Search

Nautilus Biotechnology Inc

NAUT
Add to Watchlist
1.765USD
+0.065+3.82%
Close 07-23 16:00ETQuotes delayed by 15 min
223.22MMarket Cap
LossP/E TTM

Nautilus Biotechnology Inc

1.765
+0.065+3.82%
View Detailed Chart
TradingKey Chart
Intraday
1m
30m
1h
D
W
M
D

Today

+3.82%

5 Days

+7.62%

1 Month

-24.25%

6 Months

-14.73%

Year to Date

-9.49%

1 Year

+138.19%

Key Figures
1.700Open
1.786High
528.88KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.42%Turnover Ratio
1.700Prev. Close
1.700Low
687.66KTurnover
LossP/E Static
1.42P/B
0.00%Div Yield TTM
-28.16%ROA
4.31052wk High
1.04Volume Ratio
-70.78MNet Profit
126.47MShares
-0.4517EPS TTM
0.82Beta
-33.69%ROE
0.62052wk Low
5.04%Amplitude
--Gross Margin
223.22MMarket Cap
-4.43Reward/Risk
6.31%Risk Rate

Nautilus Biotechnology Inc News

More news coming soon, stay tuned...

Earnings Forecast

Analyst Rating

Based on 2 analysts
Strong Buy
Current Rating
4.000
Target Price
+135.29%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

495
Total
6
Median
7
Average
Company name
Ratings
Analysts
Nautilus Biotechnology Inc
NAUT
2
Beigene Ltd
ONC
28
argenx SE
ARGX
27
Ionis Pharmaceuticals Inc
IONS
26
IQVIA Holdings Inc
IQV
25
Insmed Inc
INSM
23
1
2
3
...
99

Indicators

Indicators
Sell(2)
Neutral(3)
Buy(1)
Indicators
Value
Direction
MACD(12,26,9)
0.040
Neutral
RSI(14)
41.267
Neutral
STOCH(KDJ)(9,3,3)
42.730
Buy
ATR(14)
0.113
High Vlolatility
CCI(14)
-0.540
Neutral
Williams %R
59.596
Sell
TRIX(12,20)
-1.184
Sell
StochRSI(14)
100.000
Overbought
Moving Average
Sell(4)
Neutral(0)
Buy(2)
Indicators
Value
Direction
MA5
1.720
Buy
MA10
1.740
Buy
MA20
1.800
Sell
MA50
2.200
Sell
MA100
2.556
Sell
MA200
2.220
Sell

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Nautilus Biotechnology Inc Info

Nautilus Biotechnology, Inc. is a development stage life sciences company. The Company is engaged in creating platform technology for quantifying and unlocking the complexity of the human proteome. The Company is focused on transforming the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. The Company's platform end-to-end solution comprised of the proteome analysis system, consumables, and software. The Company’s products include Proteome Analysis System, and Reagent Kits. Its proteome analysis system is a high-resolution optical imaging system coupled with integrated fluidics and liquid handling sub-systems. The Company’s Reagent Kits are comprised of four main components: sample preparation, flow cell(s), multi-affinity probe reagents, and instrument buffers used to perform multi-cycle analysis runs.
Ticker SymbolNAUT
CompanyNautilus Biotechnology Inc
CEOPatel (Sujal)
Websitehttps://www.nautilus.bio/

Shareholders

Shareholders
Shareholders
Proportion
Mallick (Parag)
16.28%
Andreessen Horowitz
13.89%
Patel (Sujal M)
13.74%
Perceptive Advisors LLC
9.91%
Cercano Management LLC
5.64%
Other
40.53%

FAQs

What is the current price of Nautilus Biotechnology Inc (NAUT)?

The current price of Nautilus Biotechnology Inc (NAUT) is 1.76.

What is the symbol of Nautilus Biotechnology Inc?

The ticker symbol of Nautilus Biotechnology Inc is NAUT.

What is the 52-week high of Nautilus Biotechnology Inc?

The 52-week high of Nautilus Biotechnology Inc is 4.31.

What is the 52-week low of Nautilus Biotechnology Inc?

The 52-week low of Nautilus Biotechnology Inc is 0.62.

What is the market capitalization of Nautilus Biotechnology Inc?

The market capitalization of Nautilus Biotechnology Inc is 223.22M.

Is Nautilus Biotechnology Inc (NAUT) currently rated as Buy, Hold, or Sell?

According to analysts, Nautilus Biotechnology Inc (NAUT) has an overall rating of STRONG BUY, with a price target of 4.00.

What is the Earnings Per Share (EPS TTM) of Nautilus Biotechnology Inc (NAUT)?

The Earnings Per Share (EPS TTM) of Nautilus Biotechnology Inc (NAUT) is -0.47.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.